Jonathan Rubin - 21 Feb 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Chief Medical Officer
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
21 Feb 2025
Net transactions value
-$36,292
Form type
4
Filing time
24 Feb 2025, 20:20:14 UTC
Previous filing
21 Feb 2025
Next filing
05 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +1,875 +27% $0.000000 8,780 21 Feb 2025 Direct F1
transaction SUPN Common Stock Sale $36,292 -927 -11% $39.15 7,853 21 Feb 2025 Direct F2
transaction SUPN Common Stock Award $0 +750 +9.6% $0.000000 8,603 22 Feb 2025 Direct
transaction SUPN Common Stock Award $0 +1,250 +15% $0.000000 9,853 22 Feb 2025 Direct
transaction SUPN Common Stock Award $0 +1,250 +13% $0.000000 11,103 23 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Units Options Exercise $0 -1,875 -100% $0.000000 0 21 Feb 2025 Common Stock 1,875 $0.000000 Direct F3
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -750 -50% $0.000000 750 22 Feb 2025 Common Stock 750 Direct F4, F5
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -1,250 -25% $0.000000 3,750 22 Feb 2025 Common Stock 1,250 Direct F4, F6
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -1,250 -33% $0.000000 2,500 23 Feb 2025 Common Stock 1,250 Direct F4, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024.
F2 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3 On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.
F4 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F5 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023.
F6 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
F7 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.